Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002633 | 1.00 | MAPT (0.48) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL638191 | 0.86 | LOXL2 (0.41) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL27328329 | 0.84 | ALDH1A1 (0.46) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL8596016 | 0.79 | MAPT (0.48) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL7119359 | 0.79 | ALDH1A1 (0.48) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL18617684 | 0.79 | MAPT (0.48) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL3820241 | 0.79 | MAPT (0.48) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL25846851 | 0.79 | LOXL2 (0.52) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL21037109 | 0.79 | GABRA1 (0.47) | MAPTALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL24788998 | 0.76 | ALDH1A1 (0.46) | MAPTALDH1A1KDM4EPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116478154-A | Quinuclidine derivative and preparation method and application thereof | 北京大学宁波海洋药物研究院 | 2023-07-25 | — | — | CN | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20180258044-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| EP-3344615-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2018-07-11 | — | — | EP | disclosed |
| US-20030050475-A1 | Method for preparing halomethyl heterocyclic compounds | BURDENIUC JUAN JESUS (US) | 2003-03-13 | — | — | US | disclosed |
| EP-1277742-A1 | Method for preparing halomethyl heterocyclic compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6492517-B1 | THE PRESENT INVENTION RELATES TO A METHOD FOR PREPARING 5- AND 6-HALOMETHYL QUINOXALINES IN PRESENCE OF A RADICAL INITIATOR IN A SOLVENT SELECTED FROM THE GROUP CONSISTING OF FLUOROBENZENE, DIFLUOROBENZENES, TRIFLUOROBENZENES, | AIR PRODUCTS AND CHEMICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED | 2002-04-04 | — | — | US | disclosed |
| EP-0971895-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998043959-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5151421-A | Compounds for inhibition of metabolism of retinoids, for treatment for proliferation of epithelial cells and keratin disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-29 | — | — | US | disclosed |
| US-5028606-A | Retinoid metabolism inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-02 | — | — | US | disclosed |
| EP-0371564-A2 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | MAPT 157/4885ALDH1A1 1362/4885KDM4E 426/4885 |
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | MMP1, HCAR1, MMP13 | MAPT 4885/4885ALDH1A1 618/4885KDM4E 2476/4885 |
| US-20030050475-A1 | Method for preparing halomethyl heterocyclic compounds | HDHD5, HNMT, CBR3 | MAPT 4742/4885ALDH1A1 2209/4885KDM4E 594/4885 |
| US-20180258044-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | MAPT 157/4885ALDH1A1 1362/4885KDM4E 426/4885 |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | MAPT 157/4885ALDH1A1 1362/4885KDM4E 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.